This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Medicines Optimisation Innovation Centre (MOIC) in Northern Ireland has become a pivotal force in advancing healthcare, particularly in the essential field of medicines optimisation. In this case study, marking a decade since its inception, Katherine Redpath examines MOICs achievements, ongoing projects and future aspirations. The suboptimal use of medicines presents a significant global challenge 1 , resulting in adverse health outcomes, inefficiencies and considerable waste.
Some key public health figures are taking an extraordinary step to try to shore up U.S. vaccination policy, feared to be under threat from Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine critic. The “Vaccine Integrity Project,” which was publicly launched Thursday by the University of Minnesota’s Center for Infectious Disease Research and Policy, will be aimed at assessing the best ways for vaccine proponents to safeguard vaccination policy and
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
For the first time in over ten years, the US Food and Drug Administration (FDA) has approved a new targeted treatment for chronic spontaneous urticaria. Sanofi and Regeneron Pharmaceuticals collaborated to develop Dupixent (dupilumab). Under the FDA’s new authorisation, the therapy is indicated for individuals aged 12 years and over with the chronic inflammatory skin disease, who still experience symptoms despite taking histamine-1 (H1) antihistamine medication.
Health and Human Services Secretary Robert F. Kennedy Jr. has railed against what he sees as a “revolving door” between workers at drug companies and the Food and Drug Administration. But his department’s actions now seem to be causing that door to spin ever faster. Scores of FDA employees are searching for an exit from an agency in turmoil, particularly staff members tasked with reviewing drug applications, according to interviews with former employees and industry re
Vect-Horus has announced the appointment of Philippe Masset to the companys board of directors. This contributes to a series of senior leadership appointments which are strategic for Vect-Horus growth. Masset is a senior banking executive with a wealth of experience in investment banking, environmental, social and governance (ESG) topics, sustainable finance, and AI.
Further, the authors of the Standards of Care in Diabetes 2025 highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The federal health department is not creating a new registry of Americans with autism, a Department of Health and Human Services official said in a written statement Thursday. Instead, the official said, HHS will launch a $50 million research effort to understand the causes of autism spectrum disorder and improve treatments. The announcement arrives two days after National Institutes of Health Director Jay Bhattacharya announced the intent to create such a registry at an all staff meeting, kicki
Introduction In todays complex healthcare environment, what does it truly mean to practice Integrated Marketing Communications in pharma? For brands like Keytruda , Humira , and Ozempic , success isnt just about having a powerful product. Its about delivering consistent, engaging messages across a fragmented media landscape. Much like a symphony that requires every instrument to be in sync, pharma marketers must harmonize every touchpoint to resonate with both healthcare professionals and patien
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
High blood pressure earned its reputation as the silent killer by causing heart attacks, heart failure, and strokes. It’s also been a suspect in dementia. Some studies have hinted at a correlation between lower blood pressure and fewer dementia cases, but they were too small and too short to lend statistical significance to the link. It’s also been noted that people with untreated high blood pressure carry a 42% higher risk of developing dementia.
Introduction Pharma brands are rethinking their digital engagement strategies in 2025. With regulatory scrutiny evolving and audience expectations shifting, social media marketing plans have become a central focus for companies looking to maintain trust while expanding reach. Social platforms are no longer just optional toolsthey’re vital channels for HCP and patient engagement.
The findings support the need for improved vaccination coverage to prevent the resurgence of previously eliminated infectious diseases in the United States.
A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The debate over the future of Medicaid continues to rage among Republicans. A House budget proposal released in February would slash up to $880 billion in spending over the next decade from the public health insurance program that 80 million low-income Americans rely on — including children, seniors, and people with disabilities.
Two clinical-stage oncology programmes from Astex Pharmaceuticals have been announced by Mosaic Therapeutics, allowing it to develop targeted oncology drug combinations. This elevates the research and platform company to a clinical-stage oncology business, bringing products closer to commercialisation and market access. Mosaic now has exclusive rights to develop its combination products in these trials.
By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a
NASHVILLE, Tenn. — Robert F. Kennedy Jr.’s appearance at a major addiction and drug policy conference was marked by repeated interruptions on Thursday, as protesters and jeers forced him to pause and wait for noise to subside at least five times during his 36-minute speech. A packed and deeply divided audience at the Rx and Illicit Drug Summit, taking place at a conference center on the city’s outskirts, applauded the health secretary as he entered and exited the stage
Flemish biopharma company, Bioxodes, has announced promising results from the BIRCH phase 2a clinical trial of BIOX-101 to treat intracerebral haemorrhagic stroke (ICH). This brings the company closer to rolling out the first approved treatment for the devastating condition. The BIRCH trial, which took place with 16 patients with ICH, met both primary safety and […] The post Successful clinical outcomes for drug treating rare stroke condition appeared first on Pharmafile.
Introduction Artificial Intelligence (AI) is no longer just a futuristic concept in pharmaceutical marketingits the present and future. In 2025, AI-powered pharma marketing is transforming how companies engage healthcare professionals (HCPs), patients, and stakeholders. With evolving compliance requirements and rising demand for personalization, pharma marketers are adopting intelligent platforms to stay ahead.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I think I’ll go for a walk outside now The XBI is callin’ my name (I hear ya now) I just can’t stay uninvested all day I gotta get out get some of those bio-rays Biotechs are smilin’ Sunshine day Biotechs are laughin’ Sunshine day Every biotech seems so happy today It’
Every April 26th, World Intellectual Property (IP) Day marks a time to celebrate the creativity and innovation that fuel our economy. In 2025, the spotlight is on music—a universal language that connects people, culture and moments. But what if you couldn’t hear it? What if the joy of music was locked away, not by choice, but by biology?
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse in paediatric acute lymphoblastic leukaemia (ALL), a common childhood cancer. Led by professor Persis Amrolia, a pioneer in CAR T-cell therapy at UCL and Great Ormond Street Hospital (GOSH), the trial intends to improve outcomes […] The post ViroCell and UCL launch trial to treat childhood leukaemia relapse appeared first on Pharmafile.
Democrats recently unveiled a campaign to recruit and elect 100 doctors to public office. Democrats hope that by recruiting physicians to public office, they will be able to combat misinformation and restore trust in medicine and science. Amid a full-blown measles outbreak, the U.S. plan to withdraw from the World Health Organization, the confirmation of Robert F.
The largest clinical trial investigating a treatment for bronchiectasis has demonstrated a statistically significant reduction in the occurrence of pulmonary exacerbations.Findings from the Phase III ASPEN study of brensocatib could provide future promise for patients, as there are currently no approved treatments for the chronic inflammatory pulmonary disease.
Researchers explored whether or not hormonal contraceptive initiation is associated with increased risk of developing depression within 12 months of child delivery.
363
363
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
59 
Let's personalize your content